Why Is Regeneron Stock Sinking Monday?

Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
Open original source
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
Open original source